“…Fluorescence probes could be excellent candidates as theranostic agents for anti-AD, due to the important merits of fluorescence in biomarker sensing, such as simple operation, high sensitivity, and availability in real-time tracking. 34 Notably, near-infrared (NIR) fluorescence, including the first NIR window (NIR-I, 650-900 nm) and the second NIR window (NIR-II, 1000-1700 nm), is suitable for in vivo bioimaging in imaging-guided theranostics, owing to its inherent advantages in minimizing tissue absorption, photon scattering, and autofluorescence. 35 To date, most of the AD theranostic agents have been derived from fluorescence probes of pathological factors.…”